Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06410293 vs Adalimumab Switching Study in RA
NCT04230213Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of adalimumab-afzb in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Serum Concentration of Adalimumab at Week 30 and Area Under the Serum Concentration-Time Curve Over the Dosing Interval of Adalimumab at Week 30. Started Jan 2020; status: completed.
02
Drugs
adalimumab-afzb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04230213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230213.